Literature DB >> 14999490

Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle.

Oliver Friedrich1, Ernst Hund, Cornelia Weber, Werner Hacke, Rainer H A Fink.   

Abstract

The pathogenesis of myopathies occurring in critically ill patients (critical illness myopathy, CIM) is poorly understood. Both local and systemic responses to sepsis and other severe insults to the body are presumed to be involved but the precise mechanisms by which muscle function is impaired are far from clear. To elucidate such mechanisms we investigated the effects of blood serum fractions (5 kDa to 100 kDa molecular weight cut-off, MWCO) from patients with CIM and from control persons on membrane and contractile functions in intact mammalian single skeletal muscle fibres and chemically skinned fibre bundles. In intact fibres, resting membrane potentials were less negative when exposed to CIM serum fractions compared with control serum fractions. Half-width and maximum rise time of action potentials (AP) were smaller in CIM serum low MWCO fractions vs. control serum. Peak amplitudes of fast inward sodium currents (I(Na)) were increased by low MWCO-CIM fractions compared with control sera fractions. Additionally, voltage dependent inactivation of I(Na) was shifted towards more positive potentials by high MWCO fractions of CIM sera. In skinned fibres, pCa-force relations were similar in CIM and control serum fractions but peak force of Ca2+ induced force transients was decreased by low MWCO-CIM vs. control serum fractions. Our results (i) provide the first evidence that serum from CIM patients affects membrane excitability and the excitation-contraction coupling process at the level of the sarcoplasmic reticulum Ca2+ release of mammalian muscle fibres and (ii) also show that even control serum fractions "per se" alter the response to important physiological membrane and contractility parameters compared with physiological saline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999490     DOI: 10.1007/s00415-004-0272-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

Review 1.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 2.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 3.  Dysregulation of sodium channel gating in critical illness myopathy.

Authors:  James W Teener; Mark M Rich
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

4.  Origin of ICU acquired paresis determined by direct muscle stimulation.

Authors:  J-P Lefaucheur; T Nordine; P Rodriguez; L Brochard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

5.  IL-1α reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy?

Authors:  Oliver Friedrich; Bing Yi; Joshua N Edwards; Barbara Reischl; Anette Wirth-Hücking; Andreas Buttgereit; Roland Lang; Cornelia Weber; Fabian Polyak; Ilon Liu; Frederic von Wegner; Tanya R Cully; Aven Lee; Patrick Most; Mirko Völkers
Journal:  Am J Respir Cell Mol Biol       Date:  2014-06       Impact factor: 6.914

Review 6.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 7.  [Medically induced myopathia].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

Review 8.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

9.  Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid.

Authors:  J S Isenberg; Y Jia; L Field; L A Ridnour; A Sparatore; P Del Soldato; A L Sowers; G C Yeh; T W Moody; D A Wink; R Ramchandran; D D Roberts
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

10.  Enhanced muscle shortening and impaired Ca2+ channel function in an acute septic myopathy model.

Authors:  Oliver Friedrich; Ernst Hund; Frederic von Wegner
Journal:  J Neurol       Date:  2009-11-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.